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EPACs – epigenetic regulators that affect cell survival in cancer

Catherine Murari-Kanti, Ph.D.
University of Nebraska Medical Center, 2015
Supervisor: Michael G. Brattain, Ph.D
Cyclic adenosine monophosphate (cAMP) is a second messenger responsive to
many external stimuli, playing an important role in cellular gene expression,
metabolism, migration, differentiation, hypertrophy, apoptosis and secretion. All
of these cellular functions are important in many diseases including cancer. Most
of its effects were initially attributed to the classical protein kinase A (PKA)
protein, but cellular functions such as proliferation and migration were found to
be PKA independent and dependent on the newly discovered exchange proteins
directly activated by cAMP (EPACs). EPACs are single polypeptides that
primarily function as guanine exchange factors (GEFs) for Rap proteins that
allow the replacement of guanine diphosphate (GDP) with the more abundant
guanosine triphosphate (GTP), under cAMP stimulation.
EPAC has been reported to promote cancer cell growth and activate
phosphhatidylinositol 3-kinase (PI3K) in direct opposition to the effects of PKA.
This was confirmed in the Brattain Laboratory, treating colorectal cancer (CRC)
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cell lines with the EPAC specific activator 8CPT (8-pCPT-2-O-Me-cAMP)
induced AKT expression along with increased expression of inhibitor of
apoptosis protein (IAP) survivin and X-linked IAP (XIAP); which are implicated
with poor prognosis in cancer. However, there are 2 isoforms of EPAC – EPAC1
and 2 and to dissect which EPAC is pro-tumorigenic we used EPAC specific
inhibitors (ESI) – ESI09 (inhibits EPAC1 and 2), ESI05 (inhibits EPAC2) and
CE3F4 (inhibits EPAC1) and confirmed that EPAC1 is associated with cell
survival in CRC cell line as well as in pancreatic cancer (PaCa) cell lines.
Inhibition of EPACs decreased histone deacetylase (HDAC) 4 and 5 that are
overexpressed in many cancers. Inhibition of HDAC4 and 5 with LMK235
decreased survivin and XIAP allowing us to hypothesize that the cell survival
effects observed on EPAC inhibition must be due to the repression of HDACs 4
and 5 making EPACs epigenetic regulators.
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Chapter 1
EPACs – epigenetic regulators that affect cell survival
Catherine Murari-Kanti, Ph.D.
University of Nebraska Medical Center, 2015
Introduction:
3’,5’ -cyclic adenosine mono-phosphate (cAMP) is a second messenger produced
intracellularly by the action of adenylyl cyclase on adenosine triphosphate (ATP)
as an output of G-protein coupled receptor signaling. cAMP is involved in
multiple cell processes such as cell proliferation, metabolism, adhesion,
apoptosis, gene expression and differentiation, all of which are pivotal in
numerous diseases, including cancer [1].
The cell functions of cAMP were first thought to be solely mediated by Protein
kinase A (PKA) but it was later discovered that Exchange factor activated by
cAMP (EPAC) was also involved [2-4]. EPACs are most commonly involved as
the guanine exchange factor (GEF) for Rap proteins. Upon binding cAMP, EPAC
undergoes a conformational change that allows Rap to bind to EPAC and replace
guanosine diphosphate (GDP) with the more abundant guanine triphosphate
(GTP) [5]. In mammals, Rap guanine nucleotide exchange factors 3 and 4
(RAPGEF3 and 4) encode for EPAC1 and EPAC2 respectively. EPAC1 is
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conserved in chimpanzee, Rhesus monkey, dog, cow, rat, chicken and mouse
while EPAC2 is additionally conserved across zebra fish, fruit fly, C.elegans and
mosquito.
RAPGEF3 (EPAC1) is located on chromosome 12 and has 2 isoforms: EPAC1a
(923 amino acids) and EPAC1b (881 amino acids). For the purpose of this
document, we will be considering EPAC1a as EPAC1. RAPGEF4 (EPAC2) is
located on Chromosome 2 and has 3 isoforms – EPAC2a, EPAC2b and EPAC2c
[6, 7].
Structure of EPACs:
The N-terminus of EPAC is the regulatory domain while the C-terminus is the
catalytic domain. The cyclic nucleotide binding domain(s) (CNB) and the
disheveled-Egl-10-Pleckstrin (DEP) domain make up the regulatory domain
while the catalytic domains consist of the Ras-exchange motif (REM), Ras
association domain (RA) and the CDC25 homology domain (CDC25HD). All
isoforms of EPAC except EPAC2a possess one CNB domain. The extra CNB
domain in EPAC2A has no other effect but binds to cAMP with a 20-fold lower
affinity

than

the

shared

CNB.

The

DEP

domains

are

essential

in

compartmentalization of EPACs within the cell through protein-protein or
protein-membrane interactions [8, 9]. (Figure 1)
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The catalytic domains are highly homologous between EPAC1 and EPAC2. The
REM domain is essential for stabilizing EPAC while the RA domain in EPAC2 is
able to bind to activated Ras and allow for the transfer of EPAC2 to Ras
containing membranes in proximity to Rap [10]. This association is not observed
in EPAC1. The CDC25HD is responsible for performing the catalytic GEF activity
for Ras-like GTPases.
The regulatory region associates with the catalytic region in such fashion to
confer an auto-inhibitory configuration and thus prevent GEF activation [8].
When cAMP binds to the CNB domain of EPACs it causes the EPAC structure to
open up allowing binding of Rap-GTP. (Figure 2.)
Although EPAC has been associated with GTPase activity, some activity of this
cAMP-dependent protein appears to be independent of GTPase activity. These
effects are dependent on cellular localization.
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Figure 1. The DEP (Dishevelled, Egl-10 and Pleckstrin), CNB (cyclic nucleotide
binding domain), REM (Ras exchange motif domain), RA (Ras association
domain) and the CDC25HD (CDC25 homology domain) make up the domain
structure of EPACS. cAMP binds to the CNB domain activating EPACs.
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Figure 2: Activation of EPACs. Inactive EPAC is folded upon itself and upon
cAMP binding to the CNB domain, the structure opens up at right angles to
allow Rap-GDP to be replaced by the more ubiquitous GTP.
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Location and Functions of EPAC:
EPAC1 is more ubiquitously distributed in the body than EPAC2. There is higher
prevalence of EPAC1 in the kidney, ovary, skeletal muscle and thyroid [11].
EPAC1 levels change during development and are at their peak at about 3 weeks
after birth [12]. During interphase, EPAC1 is found on the nuclear membrane
and mitochondria and later is localized to the spindle, centrosome and contractile
ring during mitosis, in COS7 cells [9]. Varying levels of cAMP in the cell affect
the localization of EPAC1. High levels of intracellular cAMP allows for EPAC1 to
bind to phosphatidic acid via the DEP domain and bring it to the plasma
membrane, while low levels direct EPAC1 to the microtubule cytoskeleton [9, 13,
14].
EPAC2 has specific localization in the human body – in the brain, in endocrine
glands such as the pituitary and pancreas and the heart [6]. The EPAC2C isoform
is specifically observed in the liver, where it may control bile acid stimulated
canalicular formation [7, 15].
Localization and compartmentalization of EPAC depends on the availability and
the removal of cAMP. Phosphodiesterases are responsible for the degradation for
cAMP and cGMP while A-kinase anchoring proteins (AKAPs) are scaffolding
proteins responsible for retaining EPAC and allowing for downstream signaling
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to occur.[16, 17] The complex of EPAC1, PKA, mAKAP, PDE4D3 and ERK5 was
found in neonatal cardiomyocytes [18].

Physiological functions of EPAC

Cardiac Function:
- PKA is involved in cardiac contractility, relaxation and automaticity
leading to studies on the role of EPAC in cardiac function [19, 20].
- Mice in which Phospholipase C (PLC)
decrease in

was knocked out showed a

-adrenergic receptor ( AR)-dependent cardiac contraction.

PLC is downstream of EPAC and is the Rap effector [21].
- EPAC inhibits TGF

and adenosine-2 receptor induced collagen

synthesis required for profibrotic response in cardiac fibroblasts [22, 23].
- Connexin43 that is required for gap junction assembly is recruited by
EPAC via Rap1 [24]. Stressed mice expressed higher levels of EPAC1
leading to cardiac hypertrophy, confirming the role of EPAC in cardiac
function and in disease [25].

Insulin Secretion:
- Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP)
are released from gastrointestinal cells in response to glucose, which
stimulates cAMP production from pancreatic beta cells. This process was
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first thought to be mediated by cAMP on PKA but it was later found that
EPAC2 was required for the complete induction of insulin under the GLP1/GIP stimulation [26, 27].
- Rim2 (a Ca2+ tether) and Piccolo (a Rim2 interacting protein) interact
with EPAC2 to prime vesicles required for insulin secretion [27-29].
- EPAC2 and sulfonyl urea receptor 1 interact leading to the exocytosis of
insulin through the inhibition of K+ATP channels causing membrane
polarization and influx of Ca2+[30].
Due its role in insulin production, EPAC is implicated in the etiology of
diabetes and other metabolic disorders.

Cell adhesion:
Through interaction with Rap, EPAC activates the lymphocyte function
associated antigen 1, the very late activation antigen 4 and the
macrophage integrin 1 that are required for integrin-mediated cell
adhesion and E-cadherin mediated cell-cell junction formation [31-40].
8-pCPT-2'-O-Me-cAMP

(8CPT)

an

EPAC

specific

activator

was

synthesized by the Bos laboratory in 2002. This activator activated EPAC
and not PKA, thus providing an extremely useful pharmacological tool
that could be used to the study PKA-indepent effects of cAMP [41].
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8CPT allowed determination of the specific role of EPAC1 along with
Rap1 in

1-integrin-mediated adhesion. This process was cAMP

dependent and PKA independent.
Cell permeability induced by 8CPT was decreased by the knockdown of
EPAC1 or inhibition of Rap [42]. Similar results were also observed in
vascular endothelial cadherin null cells confirming that the EPAC
activator is unable to bring about cell permeability in the absence of
vascular endothelial cadherin [43]. EPAC stimulation has the ability to
increase cortical actin through the down regulation of Rho [42, 43].

Role of EPAC in Cancer:
EPAC was discovered in 1998, and the potential role of this cAMP activated
protein is being studied in cancer. EPAC has been implicated in cancer
angiogenesis, DNA damage repair, invasion and migration. cAMP is heavily
involved in myriad cancer processes, thus implying the importance of EPAC in
cancer.

Lung Cancer
Cho and colleagues determined that stimulation of EPAC1 led to a
decrease in the DNA damage repair protein - x-ray repair cross
complementing 1 and the related DNA damage apoptosis in lung cancer
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[44].

However,

Pullamsetti

and

colleagues

demonstrated

that

phosphodiesterase 4 (PDE4) – which hydrolyzes cAMP, has the ability to
decrease hypoxia inducible factor (HIF) in lung cancer cell lines. This was
further confirmed by activation of EPAC [45].
Thus, we see

pro- and anti- tumor effects of EPAC in lung cancer,

demonstrating the need for further studies of the EPAC isoforms and their
roles in tumorigenesis and metastasis.

Melanoma
Narita et al., demonstrated that both the inhibition of PDE4 and
stimulation of EPAC promoted melanoma cell growth [46]. The
Baljinnyam laboratory has done extensive work on the functions of EPAC
in melanoma and have shown that EPAC promotes translocation of
syndecan-2, a cell surface heparin sulphate (HS) proteoglycan, which
causes an increase in melanoma cell migration. Higher levels of EPAC
were found in metastatic melanoma than in the primary melanoma and
thus an increased effect on HS in metastatic versus primary tumor [47].
They have also shown that EPAC stimulation increases melanoma
migration by increasing intracellular Ca2+ via the phospholipaseC/inositol 3 (PIP3) receptor pathway that leads to increased actin assembly
[48]. The laboratory also showed that melanoma cells with higher
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expression

of

EPAC1

control

the

melanoma/melanoma

as

well

melanoma/endothelial cell communication through fibroblast growth
factor-HS interaction [49].

Ovarian Cancer
Studies on EPAC in ovarian cancer are at the nascent stage. EPAC
activation of gonadotropin stimulated human ovarian surface epithelial
cells resulted in an increase of epidermal growth factor receptor signaling
through ERK1/2 and AKT [50]. However, in ovarian cancer ES2 cells,
treatment with norepinephrine decreased migration activity through
EPAC activation of phospholipase C enzymes [51] Although there is
conflicting data regarding EPACs in ovarian cancer, its role cannot be
overlooked.

Breast Cancer
In breast cancer, EPAC activation leads to the inhibition of leptin (an
important mediator of obesity). This resulted in a decreased leptin
induced migration in highly invasive, MDA-MB-231 breast cancer cells
[52].
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Prostate Cancer
EPACs inhibit the proliferative and migratory characteristics of prostate
cancer cells. These effects are medited through mitogen activated protein
(MAP) kinase and RhoA pathways [53]. EPAC upregulates the B-Raf
(isoform of Raf1)/ERK and mammalian target of rapamycin (mTOR)
pathways to promote prostate cancer cell proliferation [54]. Though both
studies contradict each other, EPACs appear to play a role in the
progression of prostate cancer.

Pancreatic Cancer
Pro- and anti-tumor effects of EPAC have been reported in pancreatic
cancer. In one study, elevated levels of cAMP, through EPAC activation
caused a decrease in migration [55]. However, other studies suggest that
inhibition of EPAC through selective inhibitors decreases migration and
eventual progression of the disease.
EPAC1 is overexpressed in pancreatic cancer [56]. Epac specific inhibitor
(ESI) – 09, that selectively inhibits EPACs 1 and 2, decreased pancreatic
cancer cell invasion and migration. This was possible through the
activation and regulation of integrin

1.

This drug exhibited in-vivo

effects by inhibiting pancreatic cancer cell metastasis. Mice with tumors
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from pancreatic cancer cell lines, when treated with ESI09, exhibited a
decrease in metastasis to the liver as compared to the controls [57, 58].

Colorectal Cancer (CRC)
So far there have been no reported studies examining the role of EPAC in
CRC. However, the oncomine database study indicates that EPAC
expression increases as CRC progresses from adenoma to carcinoma.
(Figure 3)
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Figure 3: Oncomine data indicating the increase of EPAC expression as
CRC progresses from adenoma to carcinoma.
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Transforming Growth Factor (TGF)

Signaling Pathway:

CRC is the third most common cancer in the United States and the third most
fatal in both men and women. In 2014, there were 136,830 new cases of CRC and
50,310 resulted in death. Individuals who have adenomatous polyps diagnosed
in their life have a higher risk of developing CRC and one-third of those
diagnosed with CRC will develop metastatic disease. The death rate from CRC
has decreased over the years because of regular screenings [59]. However, there
are no effective treatments for metastatic disease. Morever, patients who present
with advanced disease are in danger of relapsing with disseminated disease.
A number of genetic changes occur in the colon for the development of fullblown cancer from a polyp and the development of metastatic disease. Changes
in genes such as adenomatous polyposis coli (APC), V-Ki-ras2 kerstin rat
sarcoma oncogene homolog (Kras), Smad4 and TGF

receptor II (TGF RII),

phosphatidyl inositol-4,5-bisphosphate 3-kinase alpha (PIK3Ca), phosphatase
and tensin homolog (PTEN), tumor protein 53 (TP53) and Bax are all
documented to play a role in the development and progression of CRC [60].
Activins, inhibins, bone morphogenetic proteins, growth differentiation factors,
anti-mullerian hormone, glial cell line-derived neutrotrophic factors and the
TGF subfamily are part of the TGF superfamily [61]. TGF has 3 isoforms TGF 1, 2 and 3 and their function is predominantly growth inhibitory in
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epithelial cells. The TGF family also plays an important role in wound healing,
angiogenesis, cell proliferation, fibrosis and cancer progression [61, 62]. The
TGF 1 isoform is the most expressed and is usually referred to as TGF .
TGF binds to the TGF receptor II (TGF RII) which autophosphorylates itself.
This causes the recruitment and transphosphorylation of TGF RI. TGF RI then
phosphorylates receptor-activated Smads (Smads 2 and 3) that then associates
with the Co-Smads - Smad4. The Smad complex then translocates into the
nucleus where it activates downstream signaling by interacting with promoter
regions of target genes. This TGF
signaling pathway [60]. (Figure 4)

signaling pathway is called the canonical
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Figure 4: Canonical TGF signaling pathway.
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TGF /PKA Signaling:
The Brattain laboratory, in 2011, discovered a non-canonical, TGF

mediated,

cAMP independent, Smad3 dependent pathway that was able to regulate cell
survival in CRC [63]. In this pathway, TGF

activated Smad3 through TGF

receptor binding. After its activation, Smad3 would bind to PKA, anchored by Akinase anchoring protein (AKAP) 149 scaffolding protein. PKA activation by
Smad3 mediates TGF

repression of survivin and XIAP. Upon cellular stress,

survivin and XIAP are released from the mitochondria and in the cytosol, they
heterodimerize to inhibit caspase activation. Activated PKA phosphorylates
survivin on Ser20 that leads to loss of formation of XIAP and survivin complex
that protects these IAPs from proteosome degradation and leads to loss of
caspase inhibition. The resulting caspase activation leads to apoptosis.
Smad3 activated PKA also phosphorylates protein phosphatase 2A (PP2A)
resulting in increased dephosphorylation of protein kinase B (AKT) on Ser473.
This inactivates AKT and prevents XIAP phosphorylation on Ser 87, required for
binding to survivin again leading to ubiquination and degradation by the
proteosome. (Figure. 5)
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Figure 5: TGF /PKA signaling pathway.
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Protein kinase A (PKA)
As noted above, PKA is one of the main effectors of cAMP and plays a central
role in the TGF

non-canonical pathway. PKA is an inactive tetramer of 4

subunits – 2 regulatory (R) and 2 catalytic (C). When cAMP binds to the 2
catalytic units, the 2 regulatory units are released and PKA can phosphorylate
various molecules. Four different genes encode the regulatory subunits. These
are PKARI , PKARI , PKARII

and PKARII . Each of these units vary in

cellular distribution as well as in functionality.
PKARI is ubiquitous while PKARI is found in the brain, testis and the B- & Tlymphocytes. Both of these subunits are found in the cytoplasm and are
associated with cell growth and proliferation. PKARII

is ubiquitously

distributed but PKARII is found in the brain, adipose and in endocrine tissues.
They vary in their expression in the cell being distributed within different
subcellular organelles as well in the cytoplasm. The RII subunits are responsible
for a marked increase in cell differentiation and a decrease in proliferation [64].
Differential binding to AKAP accounts for the differential distribution of the
subunits in the cell [65].
In cancer, an overexpression of PKARI isoforms has been observed compared to
the PKARII isoforms. PKARI is usually associated with increased proliferation
and tumor formation while PKARII is found in growth-arrested cells [66-68].
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They are involved in apoptosis through the MDM2/Bcl2 pathway and cause cell
growth arrest through the Ras/MAPK & Shh/Gli pathways and have the ability
to remodel the cytoskeleton of the cancer cell [69].
The Brattain laboratory has demonstrated that PKA can be activated through
cAMP independent, Smad3 dependent means [63]. cAMP independent activation
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- B) – where
PKAC

associates with inhibitor of

B (I- B) to form an NF- B-I- B-PKAC

complex in the inactive state, has also been observed. Upon degradation of I- B,
PKAC is released and NF B is activated [70].
Protein kinase B (AKT)
AKT is a serine-threonine kinase that has 3 isoforms - AKT1, AKT2 and AKT3.
All three isoforms are activated by phosphorylation at their highly conserved
Thr308 and Ser473 by PDK1 and mTORC1, respectively [71].
AKT1 (PKB ) is more ubiquitous found in the brain, heart and lungs and is
essential for cell growth and survival [72, 73]. It is found in the cytoplasm and is
overexpressed in many cancers, playing a role in cell proliferation in gastric
cancer [74].
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AKT2 (PKB ) is found primarily in the skeletal muscles and plays a role in
insulin secretion [75, 76]. It plays a role in cell migration and recently has been
implicated in metastasis of breast, ovarian and colon cancer [72, 77, 78].
AKT3 (PKB ) is mostly found in the brain, kidney and embryonic heart and is
localized on the nuclear membrane within the cell [79, 80]. It has been implicated
to play a role in DNA repair in breast and prostate cancer [76].
The different isoforms of AKT have their docking sites on phosphatidylinositol 3kinase (PI3K) that constitutes a major pro-survival pathway that is frequently
activated in cancer. PI3K converts to phosphatidylinositol-4,5-bis phosphate
(PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) at the plasma membrane.
mTORC2 and PI3K dependent protein kinases (PDK)1 also dock on PI3K, the
former being able to phosphorylate AKT on Thr308 and Ser473, activating it.
XIAP
XIAP is an IAP found on the X-chromosome and contains 3 BIR domains, 1 of
which binds to caspase 3 & 7 and the other to caspase 9. It also has the (ubiquitin
associated) UBA domain and a RING finger domain through which XIAP is able
to ubiquinate and degrade caspase 3 & 7 [81]. The cells’ normal function of XIAP
is associated with its release from the mitochondria to the cytosol but it also has a
nuclear function where it inhibits apoptosis by binding to tumor necrosis factor
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(TNF ) receptor associated factor (TRAF) 1 & 2[82]. XIAP is known to inhibit the
intrinsic Bcl2 pathway too [83]. It has the ability to induce NF- B and thus inhibit
cell death. XIAP has the ability to form a complex for another IAP – survivin
leading to poor tumor outcomes by inhibiting caspases.
Overexpression of XIAP is associated with enhanced chemoresistance [84], while
whole mouse XIAP knockout was non-toxic and restored chemosensititivity [85,
86]. Smac memetic peptides [87, 88], Embelin [89-91] and AEG35156 (antisense
oligonucleotide) [92, 93] are some of the recent strategies used to inhibit XIAP in
different cancer, none of which have been effectively translated into treatment
therapies. (Figure 6)
Survivin
Survivin is a unique molecule found mostly in the proliferating cells of intestinal
crypts and is otherwise barely detectable in normal or benign tissues but is
overexpressed in many cancers including lung cancer [94], osteosarcoma [95],
oral squamous cell carcinoma [96], breast cancer [97] and thyroid cancer [98].
Survivin is the smallest member of the IAP family and is encoded by the
baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) gene and has three
splice variants [99, 100]. Unique to IAPs, it contains one baculoviral IAP domain
and requires interaction with XIAP to inhibit casapases.
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There is a direct relationship between an increased presence of survivin (usually
during the G2/M phase of the cell cycle) and cancer related death because it has
the ability to inhibit apoptosis in the both the intrinsic and extrinsic pathways
[101, 102]. This increased expression is also associated with poor prognosis, high
risk of relapse and resistance to therapy [103-105]. [106]Survivin is also known to
suppress radiation induced apoptosis [106-108].
Survivin forms a complex with XIAP which inhibits caspases and this complex is
responsible for promoting survival and metastasis [109-111]. Since its presence is
high in tumor cells versus normal, survivin appears to be a promising
therapeutic target [112].
Drugs such as YM155 and FL118 are small molecule inhibitors that are capable of
suppressing survivin promoter activity [113-115]. Gene therapy was a newly
developed method to inhibit survivin which included using a dominant negative
survivin where certain amino-acid mutant substitutions in survivin (Cys84 to Ala
in the BIR domain) led to the development of a survivin molecule that acts as a
competitive antagonist to the survivin found normally in the tumor cells. This
therapy has led to decreased tumor growth through increased cell death in
breast, thymic lymphoma and gastric cancer cells [116-118]. Development of
survivin antisense oligonucleotides such as LY2181308 and SPC3042 has allowed
for the transcriptional repression of survivin [119-121]. (Figure 6)
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XIAP-Survivin complex
Survivin is usually localized in the mitochondria and upon cellular stress, is
released from the mitochondria into the cytosol where it complexes with XIAP
[109, 122]. Survivin is able to bind to all 3 BIR domains of XIAP and stabilize it.
PKA has the ability to prevent this association by phosphorylating survivin on
serine20. The complex prevents XIAP from getting ubiquinated and destroyed
allowing XIAP to promote cell survival by inhibiting caspases. This complex
formation also protects survivin, since XAF-1 (XIAP associated molecule) has the
ability to polyubiquitinate survivin, targeting it for degradation by the
proteosome. (Figure 7)
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Figure 6: Domain structure of inhibitor of apoptosis (IAP) proteins – X-linked
IAP (XIAP) and survivin.
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Figure 7: XIAP and survivin form a complex in the cytoplasm that is
cytoprotective to the cancer cells. The complex prevents XIAP from getting
ubiquinated therefore promoting cell survival by inhibiting caspases. The
XIAP-survivin complex also functions to protect survivin from degradation.
Figure was adapted from [109]
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Rationale for our study
cAMP plays an essential role in a of myriad cell functions like proliferation,
differentiation and apoptosis. These functions were initially thought to be carried
out solely by PKA. However, it became clear that various functions of cAMP
were contradictory and PKA independent. With the discovery of EPAC, some of
these contradictions were solved because EPAC can work antagonistically or
agonistically with PKA [4].
Previous work in our lab on the TGF /PKA transduceome has demonstrated that
the cAMP independent, Smad3 dependent activation of PKA led to a decrease in
XIAP and survivin expression and an overall decrease in cell survival in CRC
(apoptosis). However, there are no studies on the function of EPAC in CRC [63].
Oncomine data reveals that expression of EPAC1 and EPAC2 increases with
progression from adenoma to carcinoma. This lead us to hypothesize that EPAC
may antagonize PKA function in CRC and maybe responsible for the pro-tumor
effects of cAMP in this disease.
Work done in the Brattain Laboratory with the EPAC specific activator (8CPT)
showed an increase in the phosphorylation of AKT, and an increase in XIAP and
survivin expression. (unpublished data) Thus, we confirmed that EPAC and
PKA are acting antagonistically and the pro-survival effect observed on EPAC
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activation is specifically through EPAC and not PKA [123-125]. This implicates
EPAC as a potentially important therapeutic target in cancer.
CRC is the third most common and fatal cancer in the United States. The
statistics are even worse for pancreatic cancer (PaCa) because of its late detection
[59]. Therefore, there is a need to develop new therapies that provide benefits in
the treatment of advanced stage cancer and we hypothesize that EPAC may
represent such a target.
Inhibitors of EPAC are useful because EPAC has the ability to interact with the
TGF pathway and its inhibition would repress XIAP and survivin as well as
enhance the inhibitory effects of cAMP activated PKA on cell proliferation.
Despite the research done on EPACs over the last few years, contributions of the
specific EPAC isoforms to cancer are only now being addressed. To understand
these roles, EPAC specific inhibitors (ESI) 05, ESI09 and CE3F4 are some of the
drugs that have recently been developed.
EPAC as an epigenetic regulator:
A recent study demonstrated that cAMP signaling, through an EPAC1-mediated
inhibition of p38 MAPK, decreased the levels of histone acetyltransferase, p300
by ubiquinating it in the proteasome in lung cancer cells [126]. p300 HAT
acetylates histones opening up the chromatin structure allowing for gene
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transcription. This led us to question if EPAC represses p300 and, if so, is this
accompanied by an increased expression of HDACs that deacetylate, acetylated
histones. In both CRC and PaCa, an overexpression of histone deacetylases
(HDACs) is associated with poor prognosis and death. We will therefore test the
hypothesis that EPAC is an epigenetic regulator affecting cell survival in
cancer.
EPAC activation caused an efflux of HDAC4 and HDAC5 from the nucleus
confirming an epigenetic relationship between them [127, 128]. This nuclear
efflux is EPAC specific and was not observed with PKA activation confirming a
relationship between EPAC and HDACs [129]. Previous work in our laboratoy
has shown that the pan-HDAC inhibitor, Belinostat, causes an induction of
tumor suppressor gene - TGF RII through survivin repression [60]. We believe
that EPAC inhibition would lead to an eventual abrogation of HDAC activity as
seen with the pan-HDACi’s - causing a decrease in cancer cell survival.

Histone Deacetylases (HDACs)
Histone modifications determine chromatin structure. Acetylation of the -amino
of lysines confers negative charge opening up the DNA allowing for
transcription. In contrast, deacetylation results in closed chromatin configuration
and transcriptional repression [130, 131]. HDACs are classified into 4 main
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classes – Classes I, II, III and IV. Of these, the class III HDACs are called sirtuins
and require Nad+ for their activity while the other classes require a Zn2+ cation
for their function. There are a total of 11 HDACs plus sirtuins that comprise the
HDAC family [132, 133]. (Figure. 8)
Of particular interest to our study are Class II HDACs that are further divided
into Class IIa and IIb. Class IIa includes HDAC4, 5, 7 and 9 while class IIb
includes HDAC6 and 10. Class IIa HDACs are unique in that they have a
conserved binding site for transcription factor myocyte enhancing factor (MEF) 2
as well as 14-3-3 binding sites where there are multiple serines that get
phosphorylated and allow the HDACs to shuttle between the nucleus and
cytoplasm. 14-3-3 has a deacetylase domain for its catalytic activity towards the
C-terminal [134].

Histone Deacetylase4 (HDAC4)
HDAC4 is a Class II HDAC that is found exclusively in the brain and growing
areas of the skeleton in normal cells [135, 136]. HDAC4 is mutated in breast
cancer and melanoma and its inhibition reduces cancer cell survival [137-141].
HDAC4 is overexpressed in several cancers [142, 143]. HDAC4 is also able to
bind to HIF1-

thus protecting it from degradation and favoring tumor

progression under hypoxic conditions [144, 145]. Wilson and colleagues
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confirmed that HDAC4 promotes colon cancer cell growth through the
repression of p21 [146]. (Figure 9)

Histone Deacetylase5 (HDAC5)
HDAC5 is found exclusively in the muscles, heart and brain in normal tissue
[135, 147, 148]. The role of HDAC5 cancer hasn’t been studied in-depth yet but
there is increased expression in medullablastomas [149]. HDAC5 inherently
plays an important role in normal angiogenesis but this role in cancer
progression has not been studied. In pancreatic cancer, oxysterol binding
protein-related protein 5 (associated with poor prognosis) is indirectly
stimulated by HDAC5 [150]. (Figure 9)

Relationship between EPACs and HDACs 4 and 5
PKA is known to cause the influx of HDAC4 into the nucleus while EPACs cause
an efflux of HDAC4 into the cytoplasm [129]. EPAC activation caused HDAC4 to
efflux from the nucleus into the cytoplasm (in a Ras-dependent signaling
pathway) while HDAC5 did not. However, in the presence of HDAC4, HDAC5
was more responsive to EPAC stimulation [127, 128, 151, 152]. This confirms a
closer relationship between EPAC and HDAC4 than HDAC5.
The EPAC1/Rap1/CamKI/HDAC5 complex is involved in the placental cell
fusion, further supporting a relationship between EPAC1 and HDAC5 [153, 154].
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Pereira and colleagues, in 2015, showed that EPAC1 was more localized in the
nuclear envelope of cardiomyocytes while EPAC2 was present in abundance in
the Z-lines of these cells. On knocking out EPAC1, the nuclear export of HDAC5
was abrogated [155].
These studies point to a relationship between EPAC activation and HDAC 4 & 5
regulation but it has yet to be determined whether this relationship exists in
cancer cells and whether this interaction plays a role in cancer progression.
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Figure 8: Classification of HDACs and roles in different types of cancer.
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Figure 9: HDACs 4 and 5 belong to Class IIA and have 1084 and 1122 amino
acids, respectively. They contain a long N-terminal adaptor domain – green
rectangles are for the myocyte enhance factor (MEF) binding site; turquoise
circles indicate where chaperone protein 14-3-3 binds and is labeled with S –
serine phosphorylation; while the asterisks indicate nuclear localization
signals. The orange rectangles indicate the conserved catalytic (deacetylase)
domain.
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Challenges in studying EPACs:
Unlike PKA that has a direct assay to measure its activation there is no
direct assay to measure EPACs. The only assay that exists measures RapGTP levels which precludes analysis of any functions of EPAC that are
independent of Rap.
There is a lack of specific antibodies to EPAC1 and EPAC2 and this makes
quantification of protein expression difficult. We have a developed an IP
protocol to help circumvent these difficulties. EPAC mRNA is readily
quantifiable but this does not directly provide information of protein
expression or post-translational modifications that may affect activity.
The best available tool is an EPAC specific activator - 8CPT- that was only
developed in 2003, after the discovery of EPACs in 1998. This activator is specific
to EPAC because it contains a methyl group near the catalytic binding site that
makes it too large for interaction with PKA’s cAMP binding site. Previous work
done in our laboratory has shown that EPAC activation with 8CPT causes an
increase in cancer cell survival through an increase in XIAP, survivin and
phosphorylation of AKT. Other EPAC activator analogues have recently been
reported, these are the sulfonylureas – Tolbutamide, Glibendamide and
Glicazide. These activators are specific for EPAC2 and are able to bind to the
CNB domains [41, 147, 156-159]. However, they are not commercially available.
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Tsalkova and colleagues in 2012 developed an EPAC specific inhibitor (ESI).
ESI05 selectively inhibits EPAC2 by binding to its CNB domain [160]. ESI09
inhibits both EPAC1 & 2 and it does this by competing with cAMP for the CNB
domain on EPAC as well as inhibiting the GEF activity in both isoforms [57, 58,
159].
A new inhibitor, CE3F4, has recently been developed that inhibits EPAC1
specifically. This racemic drug exerts its inhibition allosterically – by binding to
cAMP bound EPAC1 which is in the open conformation [161]. The Courilleau
laboratory also confirmed in 2013 that the R-enantiomer has 10-fold more
selectivity towards EPAC1 than the racemic mixture [162].
For the purpose of my study, we will be examining the roles played by ESI09
(EPAC1 and 2 inhibitor), ESI05 (EPAC2 inhibitor), and CE3F4 (EPAC1 inhibitor)
in decreasing XIAP and survivin and overall cell survival in both colon and
pancreatic cancers.
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Materials and Methods
Cell culture and Reagents:
CRC cell lines were derived from patient tumors and grown in serum free (SF)
medium that contains Supplemental McCoy’s 5A (Sigma Aldrich), 5ng/ml
epidermal growth factor (EGF) (R&D Systems), 20µg/ml insulin (Sigma) and
4µg/ml transferrin (Sigma).
The FET cell line is non-tumorigenic and retains low levels of TGF signaling.
The CBS cell line retains metastatic capability. The CBSRII colon cancer cell line
was made in our laboratory using a stable transfection of the overexpression
vector of TGF RII gene with neomycin selection vector into parental CBS cells.
These same parental CBS cells without the TGF RII gene inserted were named
CBSNeo. Due to epigenetic silencing of TGF RII in the parental CBS cell lines,
the CBSNeo cell line is resistant to growth inhibition by TGF [163, 164].
The pancreatic cancer cell lines Miapaca, Capan, CFPAC and T3M4 were all
cultured in 10F medium which contained Supplemental McCoy’s 5A
supplemented with 10% FBS. Miapaca and T3M4 retain wild-type Smad4, Capan
has mutant Smad4 and CFPAC is Smad4 null.
All cell lines were grown and incubated at 37 C in a humidified atmosphere of
6% CO2.
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8CPT was obtained from Sigma Aldrich. ESI09 and ESI-05 were purchased from
Biolog. LMK235 was purchased from Selleck. The racemic mixture of CE3F4 was
first obtained from Dr. Courilleau’s lab in France and since then the racemic
mixture, and the R & S enantiomers individually were synthesized by the Amar
Natarajan Lab at the University of Nebraska Medical Center, Omaha, NE.
Western Blotting and Immunoprecipitation:
Colon cancer as well pancreatic cancer cells were plated and treated on day 3 and
day 2, respectively. Cells were washed 3 times with cold phosphate buffer saline
(PBS) that contains 0.1% EDTA. Washed cells were scraped and lysed with
TNESV buffer [50mmol/L Tris (Ph 7.5), 150mmol/L NaCl, 1% NP40, 50mmol/L
NaF,

1mmol/L

phenylmethylsulfonyl

Na3VO4,
fluoride

25μg/ml
(PMSF)

β-glycerophosphate,
and

protease

inhibitor

1mmol/L
cocktail

(Roche,Indianapolis, IN)]. Cells were lysed using a syringe, after 30min
incubation with the lysis buffer and centrifuged at 14000g’s for 20min at 4 C. The
supernantant was extracted and protein in it was quantified using the
bicinchoninic acid(BCA; Pierce). The protein was diluted in SDS sample buffer
(50mM Tris, ph 6.8, 1% SDS, 10% glycerol, 0.03% bromophenol blue and 1% βmercaptoethanol) and separated by SDS-PAGE (7.5-15% gels). The gels were
then transferred by electroblotting (100V for 90min or overnight at 10V at 4°C)
onto a nitrocellulose membrane (GE Amersham). Post transfer, the membrane
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was blocked with 5% non-fat dry milk in TBS-T (150mmol/L NaCl, 10mmol/L
Tris-HCl pH7.4, 0.05% Tween 20) for 1hr at room temperature or overnight at
4°C.

The membrane was cut at requisite molecular weights and primary

antibody was added in either 5% non-fat dry milk or 5% bovine serum albumin
(BSA) in TBS-T for 2hr at room temperature or overnight at 4°C according to the
antibody data sheets. The membrane was washed three times for 10min in TBS-T
and the appropriate secondary was added in 5% non-fat dry milk for 1hr at room
temperature. The membrane was washed three more times with TBS-T for 10min
at room temperature and the proteins were detected by the enhanced
chemiluminescence system (ECL; GE Amersham). Immunoprecipitation was
performed with 500μg of protein samples using agarose beads (Santa Cruz)
according to manufacturer’s protocol and previously established method.
(Howell 2011) Survivin (#2808), XIAP (#14334), and HDAC4 (#5392) were
purchased from Cell Signaling. EPAC1 (sc-28366) was purchased from Santa
Cruz. GAPDH (G8795) was acquired from Sigma.
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MTT and DNA Fragmentation:
The colon cancer cell lines, FET, CBSNeo and CBSRII were seeded at 5,000 cells
per well and pancreatic cancer cell lines - Miapaca (4000 cells/well), Capan (5000
cells/well), CFPAC (4000 cells/well) and T3M4 (4000 cells/well) in 96 well plates
for MTT and DNA Fragmentation. Three days following plating, colon cancer
cells were treated for the specified times and MTT/DNA Fragmentation assays
were performed on day 5. Pancreatic cancer cells were treated 2 days after
plating and assays began on day 4. 50µl of the 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) solution from Sigma was added to each
well to the existing media and incubated at 37°C for 2hr. The solution from each
cell was aspirated – which stopped the reaction and 100µl of di-methy sulfoxide
(DMSO) was added to each well and followed by shaking for 15mins at room
temperature, covered in foil. Absorbance was read at 570nm using a 96-well plate
reader.
The second 96-well plate was used to assess apoptosis. DNA fragmentation was
measured using the Cell Death Detection ELISA Plus kit from Roche according to
the manufacturer’s instructions. DNA Fragmentation results were normalized to
the MTT findings.
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Transient transfection:
On-TARGETplus SMARTpool HDAC4 siRNA was purchased from Dharmacon
(Thermo Fisher Scientific Inc., USA) and knockdown was performed according
to the manufacturer's protocol.
RNA isolation and quantitative real time PCR:

RNA was collected from treated cells using the High Pure RNA Isolation
kit (Roche Applied Science) according to the manufacturer's protocol. The
two-step quantitative PCR using TaqMan reagent was performed
according to the manufacturer's instructions (Applied Biosystems). The
mRNA expression was normalized to GAPDH. All probes were purchased
from Applied Biosystems.
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Results:
1. EPAC activation by 8CPT increases cancer cell survival.
To determine the role of EPAC in CRC we first used 8CPT – EPAC specific
activator – and examined the effect on cell survival. We hypothesized that
EPAC would mediate pro-tumorigenic effects of cAMP in opposition to
the

effects

of

PKA

as

depicted

in

the

schematic

below.

We treated the FET CRC cell line with 8CPT and observed an increased of
XIAP and survivin proteins by Western blot. (Figure 1.1) FET is a nontumorigenic CRC cell line with low TGF signaling. On treatment with
8CPT, there was no change in cell proliferation but DNA fragmentation
decreased confirming that EPAC activation was behaving antagonistically
to PKA.
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Meghan Mendick

Figure1.1: Treatment of CRC cell line FET with EPAC activator increases cell
survival associated proteins in a time-dependent manner. Data shown are
representative of three independent experiments.
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Meghan Mendick

Figure 1.2: EPAC activation has no effect on cell proliferation but decreases
DNA fragmentation therefore increasing cell survival in CRC cell line – FET.
Data shown are representative of three independent experiments.

46
2. Inhibition of EPAC1 and EPAC2 by ESI09 decreases cell survival.
The EPAC activator activates both EPAC1 and 2 isoforms. In order to
begin to dissect out the roles of the specific EPACs, we utilized the newly
developed EPAC specific inhibitors.
As EPAC activation results in an increased expression of survivin and
XIAP, we hypothesized that EPAC inhibition would inhibit cell suvival
and therefore represent a potential therapy for cancer.
We treated the CRC cell lines - FET (weak TGF

signaling; non-

metastatic), CBSNeo (no TGF signaling; highly metastatic) and CBSRII
(functional TGF signaling, poorly metastatic) as well as PaCa cell lines –
Miapaca (Smad4 wildtype), Capan (Smad4 mutant), CFPAC (Smad4 null)
and T3M4 (Smad4 wildtype) with ESI09 – selective inhibitor of EPAC1
and 2 which resulted in a decrease in cell proliferation as observed in the
MTT assay as well as an increase in cell death as observed in the DNA
Fragmentation Assay. Western Blot analysis of IAP proteins XIAP and
Survivin showed a decrease as well.
Q-RTPCR results of XIAP and survivin on treatment with ESI09 showed a
decrease too.
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Meghan Mendick

Figure 2.1: ESI09 (1um) decreased cell proliferation and increased DNA
fragmentation in the FET CRC cell line. Data shown are representative
of three independent experiments.
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Meghan Mendick

Figure 2.2: Treatment of the 3 CRC cell lines with 1um of ESI09 caused a timedependent decrease in IAP proteins confirming that EPAC inhibition causes a
decrease in cancer cell survival. Data shown are representative of three
independent experiments.
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Figure 2.3a: Treatment of Miapaca cell line with ESI09 decreased cell
proliferation and increased DNA fragmentation. Data shown are
representative of three independent experiments.
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Figure 2.3b: Western blot analysis of the treatment of Miapaca with
ESI09 demonstrated a decrease in IAP proteins thus decreasing cell
survival. Data shown are representative of three independent
experiments.
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Figure 2.3c: Treatment of Miapaca with ESI09 decreased IAP molecule
survivin at the mRNA level both at 24 and 48hrs. Data shown are
representative of three independent experiments.
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Figure 3.a: Treatment of CFPAC cell line with ESI09 decreased cell
proliferation and increased DNA fragmentation. Data shown are
representative of three independent experiments.
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Figure 3.b: Western blot analysis of the treatment of CFPAC with ESI09
demonstrated a decrease in IAP proteins thus decreasing cell survival. Data
shown are representative of three independent experiments.
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Figure 3.c: Treatment of CFPAC with ESI09 decreased IAP protein Survivin at
the mRNA level at 24hrs. Data shown are representative of three independent
experiments.
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Figure 4.a: Treatment of Capan cell line with ESI09 decreased cell
proliferation and increased DNA fragmentation. Data shown are
representative of three independent experiments.
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Figure 4.b: Western blot analysis of the treatment of CAPAN with ESI09
demonstrated a decrease in IAP proteins thus decreasing cell survival.
Data shown are representative of three independent experiments.
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Figure 4.c: Treatment of Capan with ESI09 decreased IAP molecule
survivin at the mRNA level both at 24 and 48hrs. Data shown are
representative of three independent experiments.
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Figure 5.a: Treatment of T3M4 cell line with ESI09 decreased cell proliferation
and increased DNA fragmentation. Data shown are representative of three
independent experiments.

.
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Figure 5.b: Western blot analysis of the treatment of T3M4 with ESI09
demonstrated a decrease in IAP proteins thus decreasing cell survival. Data
shown are representative of three independent experiments.
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Figure 5c: Treatment of T3M4 with ESI09 decreased IAP moleculesurvivin at the mRNA level both at 24 and 48hrs. Data shown are
representative of three independent experiments.
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3. EPAC2 selective inhibition cannot inhibit XIAP and survivin.
ESI09 inhibits both EPAC isoforms. To begin to dissect which isoform is
involved in cell survival, we utilized ESI05, which inhibits EPAC2
selectively. ESI05 binds the hinge region of EPAC2 and prevents cAMP
binding to the CNB domain. We treated the CRC cell lines - FET (weak
TGF

signaling; non-metastatic), CBSNeo (no TGF

signaling; highly

metastatic) and CBSRII (functional TGF signaling, poorly metastatic) as
well as PaCa cell lines – Miapaca (Smad4 wildtype), Capan (Smad4
mutant), CFPAC (Smad4 null) and T3M4 (Smad4 wildtype) with ESI05
and observed no change in XIAP and survivin in both the protein and
mRNA levels. Changes in mRNA levels of ESI05 were compared to that of
ESI09. No changes in cell proliferation and cell death were observed.
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Meghan Mendick

Figure 6: Expression of survivin and XIAP were unaffected in CRC cell lines –
FET, CBS and CBSRII was treated with ESI05 (EPAC2 selective inhibitor).
However, when treated with the same concentration of ESI09 (inhibits both
isoforms) there was a decrease, indicating that EPAC1 could be involved in the
cell survival effects. Data shown are representative of three independent
experiments.
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Figure 7.a: Treatment of Miapaca cell line with ESI05 did not significantly
change

cell

proliferation

or

DNA

fragmentation.

representative of three independent experiments.

Data

shown

are
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Figure 7.b: Western blot analysis of the treatment of Miapaca with ESI05
demonstrated no change in IAP proteins. Data shown are representative of
three independent experiments.
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Figure 7c: The Miapaca cell line was treated with ESI05 at 10um at 24
hours and survivin levels were compared to the ESI09 treatment at the
same concentration. Compared to ESI09 treated at 10um at 24 hours,
there is no decrease in survivin in the ESI05 treated under similar
conditions. Data shown are representative of three independent
experiments.
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Figure 7.a: Treatment of CFPAC cell line with ESI05 exhibited no significant
change in cell proliferation or DNA fragmentation. Data shown are
representative of three independent experiments.
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Figure 7.b: Western blot analysis of the treatment of CFPAC with ESI05
demonstrated no change in IAP proteins. Data shown are representative of
three independent experiments.
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Figure 8c: The CFPAC cell line was treated with ESI05 at 10um at 24
hours and survivin levels were compared to the ESI09 treatment at the
same concentration. Compared to ESI09 treated at 10um at 24 hours,
there is no decrease in survivin in the ESI05 treated under similar
conditions. Data shown are representative of three independent
experiments.
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Figure 9.a: Treatment of Capan cell line with ESI05 exhibited no significant
change in cell proliferation or DNA fragmentation. Data shown are
representative of three independent experiments.
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Figure 9.b: Western blot analysis of the treatment of Capan cell line with ESI05
demonstrated no change in IAP proteins. Data shown are representative of
three independent experiments.
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Figure 9c: The Capan cell line was treated with ESI05 at 10um at 24 hours and
survivin levels were compared to the ESI09 treatment at the same
concentration. Compared to ESI09 treated at 10um at 24 and 48 hours, there is
no decrease in survivin in the ESI05 treated under similar conditions. Data
shown are representative of three independent experiments.
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4. EPAC1 selective inhibition represses XIAP and survivin.
Selective inhibition of EPAC2 produced no detectable effects on cell
survival in either CRC or PaCa cell lines. Therefore, we hypothesized that
EPAC1 was the key isoform involved in cell survival. In order to test this
hypothesis, we utilized the selective EPAC1 inhibitor, CE3F4, that was
obtained from the Corilleau laboratory in France. They provided us with
the racemic mixture which was used to treat CRC as well as PaCa cell
lines. CE3F4 is an allosteric inhibitor of EPAC1.
Cell proliferation assays were performed and a maximal effect was
observed at 50uM. Treatment of the CRC cell lines -FET & CBS with
CE3F4 produced a decrease in XIAP and survivin at the protein level.
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Figure 10.1: Treatment of FET CRC cell line with CE3F4 -EPAC1 selective
inhibitor resulted in a decrease in cell proliferation. CE3F4 is a racemic
mixture and therefore, responses are observed at higher concentrations. The Renantiomer exhibits activity at much lower concentrations. Data shown are
representative of two independent experiments.
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Figure 10.2: The FET cell line when treated with CE3F4 (EPAC1 selective
inhibitor) reduces XIAP and survivin expression at 40µm which is the
IC50 of the racemic mixture of the drug. Data shown are representative of
two independent experiments.
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5. EPAC inhibition decreases HDACs 4 and 5.
Jeong et al demonstrated that EPAC activation causes a repression in HAT
p300. This HAT acetylates histones so we hypothesized that in addition to
decreasing the acetylating enzyme, EPACs would induce HDACs.
Therefore, we studied the effect of EPAC inhibition on HDAC expression
in our CRC cell lines. If EPACs are able to induce HDAC expression, then
inhibition should decrease expression and potentially be regarded as an
epigenetic regulator.
Treatment of our CRC cell lines with ESI09 produced a decrease in
HDACs 4 and 5. In contrast, the inhibitor produced no effect on HDAC3
expression and only a slight decrease in HDAC1 expression. These results
demonstrate that the EPACs exhibit specificity with regards to their effects
on HDAC expression.
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Figure 12a: Treatment of CRC cell lines with ESI09 decreased HDAC4 in
a dose-dependent manner. Data shown are representative of three
independent experiments.
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Figure 12b: Treatment of CRC cell lines with ESI09 decreased HDAC5 in a
dose-dependent manner. Data shown are representative of three independent
experiments.
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Figure 12.c: Inhibition of the CRC cell lines with ESI09 produced only a slight
decrease in HDAC1 but no decrease in HDAC3. Data shown are representative
of three independent experiments.
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6. Inhibition of HDAC4 and 5 by LMK235 (selective inhibitor of HDAC4
and 5) causes a decrease in cell survival.
The previous studies provide evidence that HDAC4 and 5 expression is
regulated by EPACs. This raised the question whether the regulation of
HDAC 4 and 5 was directly involved in the cell survival effects mediated
by EPAC.
We therefore hypothesized that if HDAC4 (and 5) are involved in
mediating downstream signaling of EPACs then HDAC 4 and 5 inhibition
should recapitulate the effects of EPAC inhibition on cell survival.
In order to test this, we first used the HDAC4 and 5 inhibitor, LMK235. It
is selective towards HDAC 4 and 5 in low nanomolecular levels because of
the way it is able to dock and inhibit the Zn 2+ cation required for both of
these HDACs to function [165]. This drug decreased XIAP and survivin
expression in both Smad4 wild type and Smad4 mutant (Capan) cells, in a
concentration dependent manner. This was confirmed through western
blot as well q-RTPCR.
We also examined the effect of specific HDAC4 knockdown (KD) on XIAP
expression using siRNA.
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Figure 13a: Treatment of the Miapaca cell line with LMK235 decreases XIAP
and survivin in a dose dependent manner at both 24 and 48hours. This cell
survival effect through HDAC4 and 5, points to a role of EPACs as epigenetic
regulators. Data shown are representative of three independent experiments.
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Figure 13b: Treatment of the Miapaca cell line with LMK235 decreases
survivin at the RNA level at 24hours. Data shown are representative of three
independent experiments.
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Figure 14a: Treatment of the Capan cell line with LMK235 decreases XIAP and
survivin in a dose dependent manner at both 24 and 48hours. This cell survival
effect through HDAC4 and 5, points to a role of EPACs as epigenetic
regulators. Data shown are representative of three independent experiments.
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Figure 14b: Treatment of the Capan cell line with LMK235 decreases XIAP and
survivin at the RNA level at 24hours. Data shown are representative of three
independent experiments.
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Figure 15a: Treatment of the CFPAC cell line with LMK235 decreases XIAP
and survivin in a dose dependent manner at both 24 and 48hours. This cell
survival effect through HDAC4 and 5, points to a role of EPACs as epigenetic
regulators. Data shown are representative of three independent experiments.
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Figure 15b Treatment of the CFPAC cell line with LMK235 decreases XIAP
and survivin at the RNA level at 24hours. Data shown are representative of
three independent experiments.
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Figure 16a: Treatment of the T3M4 cell line with LMK235 decreases XIAP and
survivin in a concentration dependent manner at both 24 and 48hours.,
suggesting the role of EPACs as epigenetic regulators. Data shown are
representative of three independent experiments.
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Figure 16.c: Treatment of the T3M4 cell line with LMK235 decreases XIAP and
survivin at the RNA level at 24hours. Data shown are representative of three
independent experiments.
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Figure 17: siRNA mediated HDAC4 KD decreased XIAP expression in the
Miapaca and CFPAC cells. Data shown are representative of two independent
experiments.
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Discussion:
PKA is the traditional effector of cAMP but it has since been discovered that
many cellular functions like proliferation, migration exocytosis and secretion are
PKA independent [1, 2, 166]. This opened the field to other cAMP effectors,
notably the EPACs. Misra and Pizzo in 2009 reported that PKA and EPAC
functioned antagonistically [54]. Of particular importance was the regulation of
phosphorylation of AKT – a key survival molecule in cancer that is required for
the stabilization of the IAP proteins – XIAP and survivin - PKA and EPAC
function antagonistically in the phosphorylation of AKT.
Previous work in our laboratory identified a unique TGFβ signaling
transduceome which exerted its anti-tumorigenic effects in a non-canonical TGFβ
pathway thorugh the deactivation of AKT and destabilization of XIAP and
survivin [63]. It does this by activating PKA in a cAMP independent, Smad3
dependent manner that leads to AKT dephosphorylation through PKA mediated
PP2A activation and PKA dependent survivin phosphorylation that causes
destabilization of the XIAP/survivin complex leading to the proteosomal
degradation of the IAPs.
EPACs however, promote AKT mediated cancer proliferation in an antagonistic
fashion as compared to the anti-tumor effects of PKA [54]. EPACs have been
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implicated in cancer cell migration, invasion and invadopodia formation and
form part of the TGFβRI interactome [57, 167, 168]. Thus EPACs function
antagonistically to the inhibitory TGFβ signaling effects observed in cancer cells.
Previous studies done in our lab using RAPGEF inhibitor, Brefeldin A led to a
decrease in pAKT, XIAP and survivin in CRC. When treated together with TGFβ
there was a further decrease in survivin expression.
Based on these previous findings we hypothesized that EPAC would exert protumorigenic effects through enhancement of cell survival in opposition to the
effects of TGFβ and PKA. Initially to test this hypothesis, we utilized the EPAC
specific activator, 8CPT which could not interact with PKA due to the presence
of a methyl group. EPAC activation led to increased cell proliferation, decreased
apoptosis and increased expression of the cell survival proteins survivin and
XIAP.

The EPAC activator does not distinguish between the two EPAC

isoforms. Therefore in order to determine which isoforms(s) was mediating the
cell survival effects, we utilized newly available selective EPAC inhibitors in
both CRC and PaCa cell lines.
ESI09 (inhibits EPAC1 and 2), ESI05 (inhibits only EPAC2) and CE3F4 (inhibits
only EPAC1). We discovered that inhibition of EPACs by ESI09 led to a decrease
in XIAP and survivin but this effect was not observed in cells treated with ESI05
– allowing us to hypothesize that EPAC1 is responsible for the pro-survival
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effects found in cancer. We used the racemic mixture of CE3F4 in CRC cells and
observed a decrease in XIAP and survivin confirming that EPAC1 indeed was
connected to the pro-survival role in cancer. We were then able to synthesize the
different enantiomers of CE3F4 and cell proliferation studies with these
enantiomers showed a concentration dependent decrease with the R-enantiomer
compared to the S-enantiomer and the racemic mixture. Identification of EPAC1
as the isoform responsible for pro-survival effects observed in CRC and PaCa
cancer was one of the major results from this study. These results identify EPAC1
as a potential therapeutic target for CRC and PaCa.
We examined the effect of ESI09 on HDACs. ESI09 treatment led to a decrease in
HDACs 4 and 5 which led us to hypothesize that EPACs act as an epigenetic
regulator and cause a decrease in cell survival through the inhibition of these
HDACs.
HDACs are overexpressed in many different kinds of cancers. HDAC4 is on
chromosome 2q37.3 and is involved in neuronal stabilization, bone growth and
skeletal muscle development. HDAC4 and 5 are Class II HDACs that shuttle
between the cytoplasm and nucleus. Certain signals will allow HDAC4 to
interact with 14-3-3 and enter the cytoplasm [169]. Importin is another protein
that HDAC4 interacts with to efflux from the nucleus into the cytoplasm [170].
HDAC4 along with HDAC5 when overexpressed decreased the βcells (produces
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insulin) and the δcells (produces somatostatin) of the pancreas indicating their
role in diabetes [171]. HDAC4 directly interacts with tumor suppressor microRNA22 and downregulates it in hepatocellular cancer and inhibiting HDAC4
increases micro-RNA22 decreasing cell proliferation of hepatocellular cancer
cells [172]. Platinum chemoresistant ovarian tumors had an increased level of
HDAC4 compared to the non-chemoresistant tumors [173]. Compared to the
normal bladder cells, HDAC4 was found at higher levels in the tumor cells [174].
HDAC4 is mutated in breast cancer and melanoma [141]. HDAC5 also is
important in cancer but its role so far appears to be mostly in angiogenesis [175].
HDAC5 also regulates PTEN in PaCa and plays a role in cancer cell proliferation
[149, 150].
EPAC activation is known to cause an efflux of HDAC4 from the nucleus into the
cytoplasm. HDAC5 was not responsive to this activation [127]. Activation of
EPAC also causes a decrease in HAT p300 levels allowing us to hypothesize that
if EPAC activation is causing a decrease in HAT levels and an increase in HDAC
levels (efflux from nucleus) then EPAC inhibition must cause a decrease in
HDACs, therefore EPAC behaves as an epigenetic regulator.
Inhibition of EPACs by ESI09 caused a decrease in the levels of HDAC4 and 5.
Of importance is the relationship between HDAC4 and hypoxia inducible factor
1-α (HIF1-α). HIF1-α is part of the hypoxic response that is found in most solid
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tumors and is responsible for the generation of survival pathways by
upregulating protein responsible for angiogenesis and anaerobic metabolism
[176-178].
Inhibitors of HIF-1α or circumstances that can mitigate it may be beneficial in
many solid tumors. ESI09 causes a decrease in HDAC4 and 5 – of importance to
this study is the decrease in HDAC4.

HDAC4 regulates HIF1-α’s acetylation and stability because it directly interacts
with HIF1-α through its multiple lysines. When HDAC4 and 5 bind to HIF1-α,
binding of FIH-1 (factor inhibiting HIF1-α) is prevented and association with
p300 (HAT) is increased – causing increased stability of HIF1-α. Inhibition of
HDAC4 leads to deacetylation of HIF1-α and eventual degradation because of
lack of stability in non-small cell lung cancer. Panobinostat (pan-HDAC
inhibitor) when given in combination with cisplatin exhibited higher levels of
apoptosis and reduced tumor growth in non-small cell lung cancer. HDAC4
inhibition was also responsible in the reduction of glycolysis (hypoxia related)
and chemoresistance to docetaxel [144, 179, 180]. Thus, HDAC4 presents itself as
an exciting therapeutic target for the treatment of cancer.

PaCa cell lines when treated with ESI09 (inhibits EPAC1 and 2) showed a
decrease in HIF1-α.
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We inhibited HDAC4 and 5 using the drug LMK235 and observed a decrease in
XIAP and survivin. Knocking down HDAC4 with siRNA also showed a similar
effect.
Thus the inhibition of EPAC plays an important role in cell apoptosis and tumor
progression. EPAC when inhibited will decrease the levels of HDAC4 and 5 and
this in turn will cause the destabilization and degradation of HIF1-α. EPAC1
may represent a therapeutic target and CE3F4 represents a prototype drug to
develop for therapy.

Future Directions:
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1. Synthesize different enantiomers of CE3F4 and treat CRC cells and PaCa
cells to confirm the role of EPAC1 in the progression of cancer.
2. Develop stable inducible knockdowns of EPAC1 and 2 and confirm their
role in cell survival.
3. Confirm the relationship between HDAC4 and HIF1-α. Perform hypoxic
studies with a combination of CE3F4 and LMK235.
4. Generate stable knockdowns of HDACs 4 and 5.

Conclusions:
EPAC1 enhances pro-survival signaling in CRC or PaCa. My research in this part
of the dissertation has shown that EPACs, particularly EPAC1 behaves as an
epigenetic regulator and is able to regulate cancer cell survival. Published
literature has thus far not shown any relationship between epigenetics and EPAC
making this a novel finding.
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Abstract
Identification of epigenetic targets responsible in silencing tumor suppressor
gene - TGF RII in Colorectal Cancer
Catherine Murari-Kanti, Ph.D.
University of Nebraska Medical Center, 2015
Advisor: Michael G. Brattain, Ph.D
Colorectal cancer is the 3rd leading cause of cancer deaths in the United States.
Activation of oncogenes and silencing of tumor suppressor genes (TSG)
contribute to the development and progression of colorectal cancer. One such
TSG is the transforming growth factor β receptor II (TGFβRII) which results in
loss of growth inhibitory TGFβ signaling and is a common event in cancer
progression. Although mutation of this TSG is common, especially in tumors
which exhibit microsatellite instability there is increasing evidence that TGFβRII
is epigenetically silenced in many different cancers.

Restoration of TGFβ

signaling by re-introduction of TGFβRII results in anti-cancer effects in colon and
other cancer cell lines.
Histone deacetylases (HDACs) are involved in the mechanism of epigenetic
silencing. These enzymes remove the acetyl groups from lysine tails of histones
usually resulting in gene repression. HDACs are classified into 4 groups (Classes
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I, IIa, IIb, III and IV) and, except for Class III, need the zinc cation for their
function. Deacetylation by Class III HDACs (Sirtuins) is NAD+ mediated. Histone
deacetylase inhibitors (HDACi) have recently entered clinical trials and are
effective in inhibiting growth and inducing apoptosis in many hematological
malignancies but results against solid tumors as single therapies has been
disappointing. A significant effect of these drugs is reactivation of TSGs via
histone deacetylation inhibition which results in alterations in the chromatin
permitting transcription of these silenced genes.
Our laboratory has previously demonstrated that the pan HDACi Belinostat,
which inhibits Class I and II HDACs, effectively induced TGFβRII expression in
cancer cell lines with epigenetically silenced receptor restoring TGFβ
downstream signaling effects including the TGFβ dependent decrease in
survivin. Therefore, HDACi provide a potential therapy to restore the growth
inhibitory and apoptotic effects of the TGFβ inhibitory pathway. We hypothesize
that the identification of the specific HDACs involved in reactivation of
epigenetically silenced TGFβRII would allow the use of more specific HDACi’s
which would increase the therapeutic index of these drugs, decrease side effects
and permit more effective use in combination therapies.
We are using both genetic and pharmacological approaches to identify the
specific HDACs involved in reactivation of TGFβRII. We have performed
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lentiviral shRNA knockdown of HDAC1, 2 and 3 and observed that KD of
HDACs 1 and 3 caused the induction of TGFβRII. However knock down of
HDAC2 had no effect on TGFβRII expression. Treatment of colon cancer cells
which exhibit epigenetically silenced TGFβRII with the HDACi Mocetinostat,
specific for the Class I HDACs1, 2, 3 and 11, resulted in robust TGFβRII
expression. However, treatment with Droxinostat, specific for HDACs 6 and 8,
and at higher concentrations HDAC3, did not result in TGFβRII induction until
concentrations effective in inhibiting HDAC3 were achieved. Treatment of colon
cancer cells with histone methyltransferase inhibitors – UNC0638 and DZNEP –
G9a and EZH2 inhibitors respective induced TGFβRII. HDAC inhibitors are able
to induce TGFβRII but also cause a decrease in histone methyl transferases G9a
and EZH2 confirming their role in the silencing of TSG TGFβRII.

112

Introduction:
Colorectal Cancer (CRC)
CRC is the the 3rd most common cancer and the 3rd most fatal cancer in the
United States. According to the American Cancer Society, 136,830 men and
women were diagnosed with CRC in 2014, out of which 50,310 died from the
disease. This cancer develops slowly over a period of 5-10years [181].
Contributing factors include sedentary lifestyle, obesity and a diet rich in red
meat but lacking in fresh fruit, vegetables and fiber[182-185]. Regular
colonoscopies (screening) have improved outcomes with early detection.
However, 1/3rd of patients diagnosed with CRC have advanced disease with
metastases or will relapse with metastatic disease. The 5-year survival rate for
patients with distant metastasis is 12% [186]. There is a need to understand the
progression of the disease from normal to carcinomas to metastatic disease as
well as develop therapies that will combat advanced CRC at each step.
Multiple genetic mutations are responsible for normal colon epithelium to
develop into a cancerous tissue [187]. (Figure1) Early studies on CRC have
determined the genetic targets in CRC with the help of 2 inherited syndromes –
Familial Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis Colorectal
Cancer (HPNCC) also known as the Lynch syndrome [188-191].

The
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adenomatous polyposis coli (APC) protein is involved in cell cycle regulation,
cell death and proliferation and plays a central role in FAP where benign polyps
develop from the normal colon. Mutation of the APC gene allows for the
aberrant proliferation of the colon cells. Benign polyps then progress to form
adenomas and eventually into full-blown carcinomas [192, 193].
Lynch syndrome occurs when an inherited mutation occurs in the mismatch
repair genes (MMR) which include – MutL homolog 1 (MLH1), MutS protein
homolog 2 (MSH2), MutS homolog 6 (MSH6) or postmeiotic segregation
increased 2 (PMS2) [194]. Insertions or deletion mutations that occur in any one
of these genes at the nucleotide repeat sequences also known as microsatellites
cause microsatellite instability (MSI) and this is common in many tumor
suppressor genes (TSG) like transforming growth factor receptor (TGFβRII) [195197]. Around 30% of all tumors in CRC have TGFβRII mutations [198].
CRC progresses from a benign polyp to an adenomatous polyp. If detected at
this stage and surgically excised, the patient is rescued from cancer development.
If not removed, the adenomatous polyp may progress into an adenoma (surgery
+ chemotherapy), to carcinoma (radiation, surgery and chemotherapy) and
finally to metastatic disease to other organs in the body. Genes such as APC, Kras, p53, Smad4 and TGFβRII are mutated in CRC [199-203].
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Figure 1. Genetic changes in different genes involved in tumorigenesis and
progression of CRC.
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TGFβ signaling pathway
TGFβ signaling generates a growth inhibitory pathway that is pivotal in tumor
suppression in CRC. It has been reported that TGFβ signaling can promote
tumorigenesis in advanced stages of other cancers, particularly breast cancer
[204]. However, the Brattain Laboratory has demonstrated that reconstitution of
TGFβ receptors into cell lines lacking receptor expression inhibits progression
and metastasis [205].
The TGFβ family comprises 3 isoforms – 1, 2 and 3, that possess a high degree of
homology and are part of a family of structurally related proteins such as the
activins, inhibins, bone morphogenetic factors, growth differentiation factors,
glial cell line-derived neurotrophic factors and anti-mullerian hormones [62, 206209]. The TGFβ1 isoform is the most abundant and is often referred to TGFβ.
TGFβ functions through the TGFβ receptors I and II (TGFβRI and TGFβRII) that
are serine threonine kinases [210]. TGFβ binds to TGFβRII and causes it to
autophosphorylate itself leading to activation of the TGFβ canonical pathway.
Phosphorylated TGFβRII sequesters TGFβRI and trans-phosphorylates it.
TGFβRI in turn phosphorylates the receptor-Smads (R-Smads which are Smads 2
and 3) that associate with the Co-Smads (Smad4). This entire Smad complex then
translocates to the nucleus where it interacts with promoter regions of different
downstream genes [211].
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Figure 2: The canonical TGF signaling pathway.
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Epigenetic Silencing of TGFβRII
Mutation of TGFβRII is common microsatellite instability CRC. However,
TGFβRII is commonly lost in microsatellite stable CRC. This is achieved through
epigenetic silencing. Many studies have shown that neither promoter mutation
nor DNA methylation is responsible for the silencing of TGFβRII. Chromatin
immunoprecipitation (ChIP) revealed that at the TGFβRII promoter there was a
decreased histone 3 (H3) acetylation and an increased histone3lysine9
trimethylation (H3K9) – suggesting that epigenetic changes (silencing) of the
TGFβRII promoter are responsible for its loss in cancer. These epigenetic changes
are mediated by histone deactylases (HDACs) or histone methytransferases
(HMTs) [212, 213].

Histone Deacetylases
The acetylation status of the -amino of lysines on histones renders chromatin
active or inactive. The addition of the negative charge opens up the chromatin
structure for active transcription Hyperacetylation is associated with active
transcription while hypoacetylation is responsible for gene repression [130, 131].
(HDACs are classified into 4 main classes – Classes I, II, III and IV. Of these, the
class III HDACs are called sirtuins and require Nad+ for their activity while the
other three classes require a Zn2+ cation for their function. There are a total of 11
HDACs plus sirtuins that fall in the HDAC category [132, 133].
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HDACs are overexpressed in many kinds of cancers including CRC and are
usually associated with poor prognosis [214-221]. (Figure 3) Osada and coworkers studied the epigenetic silencing of TGFβRII in lung cancer cell lines and
showed increased H3K9 methylation (silencing) and decreased H3K4 (activation)
leading to increased TGFβRII silencing [222, 223].
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Figure 3: Classification of HDACs and their status in different cancers.
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Histone methytransferases (HMTs)
Histone methylation usually occurs on -lysines of histones 3 and 4 and can be
associated with both gene activation and silencing [130, 224]. G9a is an HMT that
catalyzes the histone-3 lysine-9 methylation (H3K9me) and this reaction is
usually associated with euchromatic gene silencing. G9a and G9a-like protein
partner with each other and are responsible for the H3K9methylation, which can
be either mono- or di-methylation [225, 226].
EZH2 is yet another HMT that is part of the polycomb repressive complex and is
responsible for H3K27 methylation that is again associated with gene silencing
[227]. The roles of HMTs in the silencing of TGFβRII have not been studied yet
but since there is plasticity in epigenetic silencing, it is likely that methylation
works in concert with deacetylation to produce the observed transcriptional
repression [227, 228].

HDAC inhibitors (HDACi’s)
HDACs are aberrantly overexpressed in different cancer and therefore present
themselves as excellent therapeutic targets. Development of the different
HDACi’s was based on their chemical structure and their ability to obstruct the
Zn2+ cation that is required for HDAC activity [229, 230]. The pan-HDACi’s are
selective for Class I, II and IV HDACs but do not affect sirtuins [231]. Initial pan-
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HDACi’s inhibited all HDACs to differing degrees but more class selective
HDACi’s are now becoming available [232, 233].
The different chemical groups are as follows:
1. Hydroxamic acids (TSA and Vorinostat)
2. Carboxylic acid (Valproate and Butyrate)
3. Aminobenzamides (Etinostat and Mocetinostat)
4. Cyclic peptides (Apicidin, Romidepsin)
5. Epoxyketones (Trapoxin)

MGCD0103 (Mocetinostat)
This is an aminobenzamide HDAC inhibitor that inhibits HDACs 1, 2, 3
and 11 at nanomolecular ranges and is most effective against HDACs1
and 2. It has the ability to prevent cell proliferation, cause cell cycle arrest
with the induction of p21 and is active in-vitro for about 48hrs. The drug
is knows to affect only cancer cells and not normal human cells, so
providing a therapeutic index [234-238].

Droxinostat
This HDACi is a hydroxamic acid moiety that inhibits HDACs 3, 6 and 8
and is able to cause cancer cell death by activating the death ligands FAS
and tumor necrosis factor related apoptosis inducing ligand. The
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hydroxamic acid moiety is important for its function. It inhibits HDAC 6
and 8 at much lower concentrations than it does HDAC3 [239, 240].
HMT inhibitors:
These inhibitors have the ability to prevent the methylation of histones and so
permit the transcription of TSGs.

Drugs developed against HMTs include

UNC0638 (G9a inhibitor), EPZ004777 (DOTL1 inhibitor), AZO5 (SMYD2
inhibitor) and DZNEP (EZH2 inhibitors) [241].

UNC0638 (UNC)
It is a selective inhibitor of G9a and GLP in the low nanomolar range. It
functions by blocking the enzymatic activity of G9a/GLP and therefore
does not affect protein or mRNA levels. It inhibits H3K9 methylation with
high potency and low toxicity [242, 243].

DZNEP
This selective inhibitor of EZH2 exhibits only mild toxicity against normal
human cells. The drug has proven to be anti-tumorigenic in breast, lung,
brain, prostate and liver cancer. It has the ability to inhibit cell migration
and invasion. DZNEP when combined with HDACi Panobinostat had
better outcomes in Acute myeloid leukemia [244-248].

123

Rationale and Hypothesis:
The Brattain Laboratory has shown that introduction of TGFβRII through
genetic expression into CRC with epigenetically silenced receptor decreases
tumorigenecity and metastatic capacity. Conversely, introduction of a dominant
negative TGFβRII into the FET CRC cell line, which retains low levels of TGFβ
signaling, results in acquisition of tumorigenecity in vivo. Therefore, reactivation
of expression of TGFβRII in CRC, where this tumor suppressor gene (TSG) is
epigenetically silenced might represent a potential useful therapeutic strategy
given the growth inhibitory and anti-metastatic effects of the TGFβ signaling
pathway. The development of epigenetic drugs affords an opportunity to utilize
this potential therapeutic benefit. However, current HDACi’s inhibit all classes of
HDACs except the sirtuins. Identification of the epigenetic enzymes (HDACs
and HMTs) involved in the epigenetic silencing of TGFβRII would allow for the
development of improved therapy, due to fewer off target effects.
Previous work in our lab demonstrated that pan-HDACi Belinostat was able to
induce the expression of the TSG TGFβRII in CRC cell lines with epigenetically
silenced TGFβRII. Induction of TGFβRII was associated with decrease in
inhibitor of apoptosis (IAP) proteins X-linked IAP (XIAP) and survivin [211].
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Belinostat is a pan-HDAC and inhibits all classes of HDACs except Class III
HDACs (sirtuins) and therefore is associated with higher incidence of side and
off-target effects[249]. Therapy would be improved by the development of more
selective HDACs. Therefore there is a need to discover the HDACs responsible in
the silencing of TGFβRII and develop therapeutic HDACi’s to target them. The
TGFβRII promoter lacks a specific transcription start site (no TATA box) but
contains GC boxes, which bind Sp1 and Sp3. The Brattain laboratory reported
that on HDACi treatment, Sp3 becomes acetylated by p300. Sp1 and Sp3 are
bound to HDACs that cause TGFβRII to stay in an inactive state. On treatment
with HDACi TSA, acetylated Sp3 along with Sp1 acts as a transcriptional
activator leading to the reactivation of expression of TGFβRII [250]. (Figure 4)
The induction of TGFβRII upon treatment with pan-HDACi’s points to an
essential role of HDACs in the silencing of TGFβRII. Futher, although histone
methylation status changes with TGFβRII induction, the HMTs involved in
TGFβRII silencing have not been studied [223].
Therefore we hypothesize that the identification of the specific HDAC/HDACs or
HMT/HMTs involved in the reactivation of epigenetically silenced TGFβRII
would allow the use of more specific HDACi’s/HMT inhibitors which would
increase the therapeutic index of these drugs, decrease side effects and permit
more effective use in combination therapies.
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Figure 4: Effect of HDACs on the promoter region of TGF RII.
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Materials and Methods:
Cell culture and Reagents
CRC cell lines were derived from patient tumors and grown in serum free (SF)
medium that contains Supplemental McCoy’s 5A (Sigma Aldrich), 5ng/ml
epidermal growth factor (EGF) (R&D Systems), 20µg/ml insulin (Sigma) and
4µg/ml transferrin (Sigma).
The FET cell line is non-tumorigenic and retains low levels of TGF signaling.
The CBS cell line retains metastatic capability [163, 164].
All cell lines were grown and incubated at 37 C in a humidified atmosphere of
6% CO2.
MGCD0103 (S1122) and Droxinostant (S1422) were purchased from Selleck,
while UNC0638 (U4885) and DZNEP (SML0305) were purchased from SigmaAldrich.
Western Blotting and Antibodies:
Colon cancer as well pancreatic cancer cells were grown to the required number
days for confluence after drug treatment. Cells were washed 3 times with cold
phosphate buffer saline (PBS) that contains 0.1% EDTA. Washed cells were
scraped and lysed with TNESV buffer [50mmol/L Tris (Ph 7.5), 150mmol/L NaCl,
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1% NP40, 50mmol/L NaF, 1mmol/L Na3VO4, 25μg/ml β-glycerophosphate,
1mmol/L phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor cocktail
(Roche,Indianapolis, IN)]. After 30min incubation with the lysis buffer, cells were
centrifuged at 14000g’s for 20min at 4 C. The supernatant was extracted and
protein in it was quantified using the bicinchoninic acid(BCA; Pierce). The
protein was diluted in SDS sample buffer (50mM Tris, ph 6.8, 1% SDS, 10%
glycerol, 0.03% bromophenol blue and 1% β-mercaptoethanol) and separated by
SDS-PAGE (7.5-15% gels). The gels were then transferred by electroblotting
(100V for 90min or overnight at 10V) onto a nitrocellulose membrane (GE
Amersham). Post transfer, the membrane was blocked with 5% non-fat dry milk
in TBS-T (150mmol/L NaCl, 10mmol/L Tris-HCl pH7.4, 0.05% Tween 20) for 1hr
at room temperature or overnight at 4°C. The membrane was cut at requisite
molecular weights and primary antibody was added in either 5% non-fat dry
milk or 5% bovine serum albumin (BSA) in TBS-T for 2hr at room temperature or
overnight at 4°C according to the antibody data sheets. The membrane was
washed three times for 10min in TBS-T and the appropriate secondary was
added in 5% non-fat dry milk for 1hr at room temperature. The membrane was
washed three more times with TBS-T for 10min at room temperature and the
proteins were detected by the enhanced chemiluminescence system (ECL; GE
Amersham). TGF RII (sc-177799) antibody was purchased from Santa Cruz.

128
pSmad3 (#9520) HDAC1(#2062), HDAC2(#5113), HDAC3(#3949), Survivin
(#2308), G9a (#3306) and EZH2(#5246) antibodies were purchased from Cell
Signaling. GAPDH (G8795) was acquired from Sigma.
Transient transfection:
HDAC2 (sc-29345) and HDAC3 (sc-35538) siRNA were purchased from Santa
Cruz Biotechnology Inc., and knockdown was performed according to the
manufacturer's protocol.
Stable transfection:
HDAC1 shRNA (sc-29343) was purchased from Santa Cruz Biotechnology Inc.
FET and CBS cell lines were plated in 10cm plates in serum free medium which
was changed to Opti-MEM media (Invitrogen), when they were 40% confluent.
The cells were transfected with a pool of 3 shRNA’s directed against HDAC1.
Two stable clones were selected and used in this study.
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Results:
1. MGCD0103 induces TGF RII (RII) in colon cancer cells and reduces cell
survival.
In order to begin to dissect the specific HDACs involved in the epigenetic
silencing of TGF RII, we used some of the newer generation HDACi’s
which exhibit a more limited range of HDAC selectivity. Mocetinostat
(MGCD0103) inhibits HDACs 1, 2, 3 and 11. We first tested the effect of
this drug on the CBS cell line that has an epigenetically silenced TGF RII,
and FET cells which retain a low level of TGF

signaling. MGCD0103

induced increased TGF RII expression by 48hrs. (Figure 1a) The induction
was dose dependent. This induction of TGF RII was accompanied by a
dose-dependent decrease in IAP protein, survivin.
We next determined whether MGCD0103 would induce TGF RII
expression in the CBS CRC cell line that has an epigenetically silenced
TGF RII and lacks functional TGF signaling. Again MGCD0103 induced
TGF RII expression by 24hours, accompanied by decreased survivin.
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Figure 1a: Mocetinostat (MGCD) inhibits HDACs 1, 2, 3 and 11 and
induces expression of TGF RII at 48hours in a dose dependent manner,
accompanied by a decrease in IAP protein, survivin; in the FET CRC cell
line. Data shown are representative of three independent experiments.
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Figure 1b: Mocetinostat (MGCD) inhibits HDACs 1, 2, 3 and 11 and
induces expression of TGF RII at 48hours in a dose dependent manner,
accompanied by a decrease in IAP protein, survivin; in the CBS CRC
cell line which has epigenetically silenced TGF RII. CBS cells were
treated with Belinostat, a pan-HDACi at 500nm for 48hrs as a positive
control.

Data
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2. Inhibition of HDACs 3, 6 and 8 by Droxinostat does not induce
TGF RII in CRC cell lines.
Droxinostat inhibits the ClassII HDACs 6 and 8 with IC50 of 2.47 and 1.46
µm, respectively, with inhibition of HDAC3 at around 10-fold higher
concentrations. Treatment of the CBS CRC cell line, which has
epigenetically silenced TGF RII, with Droxinostat did not induce TGF RII
at 10um. TGF RII expression was restored to control level at 25µm which
would correspond to the same concentration at which HDAC3 inhibited.
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Figure 2. Treatment of the CBS CRC cell line with Droxinostat saw no
induction of TGF RII at the lower concentrations but levels equivalent
to the control at higher concentrations, when HDAC3 would get
inhibited. Data shown are representative of three independent
experiments.
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3. Genetic approaches to confirm that HDAC1 and HDAC3 are involved in
the epigenetic silencing of TGF RII.
The drug studies indicate that HDAC1 and HDAC3 may be key players in
the epigenetic silencing of TGF RII. Therefore, we performed stable
knockdown (KD) of HDAC1, generating clones 7 and 9 in the FET CRC
cell line and clones 6 and 17 in the CBS CRC cell line. siRNA was used to
knock down HDACs 2 and 3 and TGF RII expression was determined.
KD of HDAC2 was performed as a control to confirm that only the KD of
HDAC1 and HDAC3 resulted in increased TGF RII expression.
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Figure 3a: KD of HDAC1 in both the FET and CBS CRC cell lines
caused the re-expression of TGF RII.
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Figure 3b: KD of HDAC2 in both the FET and CBS CRC cell lines did
not induce TGF RII expression. Data shown are representative of three
independent experiments.
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Figure 3c: KD of HDAC3 in both the FET and CBS CRC cell lines caused
the re-expression of TGF RII. Data shown are representative of three
independent experiments.
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4. The role of HMTs G9a and EZH2 in the epigenetic silencing of
TGF RII.
The role of HDACs in the epigenetic silencing of TGF RII has been well
established.

However,

epigenetic

silencing

also

involves

histone

methylation. We hypothesized that HMTs activity might be involved in
the epigenetic silencing of TGF RII. Therefore in order to address whether
HMTs are involved in the silencing of TGF RII we used specific G9a and
EZH2 inhibitors, UNC0638 and DzNEP, respectively.
Treatment of CRC cell lines CBS with UNC0638 allowed for the reexpression of TGF RII in a time dependent manner- with maximal effect
at 48 hours and in a dose dependent manner. Whole cell lysates from FET
cells treated with Belinostat were run as positive control.
To confirm that the inhibition of G9a was inducing the expression of
TGF RII and reactivating the TGF inhibitory pathway, we examined the
phosphorylation

status

of

Smad3

upon

phosphorylated when the canonical TGF

activation.

Smad3

is

pathway is activated. Smad3

was activated following drug treatment of the cells.
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Figure 4: Treatment of CBS cell line that has epigenetically silenced TGF RII,
with UNC0638 (UNC), induced TGF RII in a time and dose-dependent
manner. pSmad3 induction confirmed the activation of the canonical TGF
signaling pathway. Data shown are representative of three independent
experiments.
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5. Inhibition of HMT DzNEP induces expression of TGF RII in a time
and dose-dependent manner.
Treatment of CRC cell line CBS with DzNEP allowed for the re-expression
of TGF RII in a time-dependent manner with a maximal effect at 48 hours
and in a dose-dependent manner at both 24 and 48 hours. Whole cell FET
lysates treated with Belinostat were used a positive control.
To confirm the re-expression of TGF RII, through the inhibition of EZH2,
was reactivating the TGF inhibitory pathway, we investigated the effect
of DzNEP on Smad3 phosphorylation.by adding TGF to the DzNEP
treated cells, 1 hour before harvest and as observed in CBS cells, DzNEP
treatment was associated with Smad3 activation.
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Figure 5: Treatment of CBS cell line that has epigenetically silenced TGF RII,
with DzNEP, induced TGF RII in a time and dose-dependent manner.
pSmad3 induction confirmed the activation of the canonical TGF signaling
pathway. Data shown are representative of three independent experiments.
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6. Interaction between HDACs and HMTs in the epigenetic silencing of
TGF RII.
Our data indicate that HMTs are involved in the epigenetic silencing of
TGF RII as inhibition of those enzymes results in the induction of
TGF RII expression. However, HDAC inhibition alone is sufficient to
induce TGF RII expression without additional HMT inhibition. Therefore,
we hypothesized that HDAC inhibition might decrease HMT activity
allowing for HDAC inhibition alone to induce expression of TGF RII.
Conversely, we examined the effect of the HDACi Belinostat on the
expression of G9a and EZH2. Belinostat treatment of FET CRC cells
resulted in a dose-dependent decrease in G9a and EZH2 24 hours.
Previous work done in the Brattain laboratory has confirmed that panHDACi, Belinostat, is able to reactivate the TGF signaling pathway
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Figure 7: Treatment of FET CRC cell line with Belinostat decreases HMTs, G9a
and EZH2 confirming the dual role of HDACi’s of inhibiting HDACs as well
as regulating HMT status at gene promoters. Data shown are representative of
three independent experiments.

144

Discussion:
The mutational changes underlying the development and progression of CRC
have been well documented [192]. Mutations in TSG’s or oncogenes result in TSG
silencing or oncogene activation. These mutational changes are common in the
microsatellite instability phentoype of CRC [251, 252]. However, recently the
importance of epigenetic changes, which lead to TSG silencing or oncogene
activation, have been recognized [253-255]. Epigenetic regulation involves
modification of DNA histones or other DNA binding proteins that affects
chromatin conformation that either activates or represses transcription of genes
at the altered site.
DNA methylation and histone modifications are two such epigenetic events that
occur in the cell. Histone modifications include acetylation and/or methylation of
the lysine tails of the histones around which DNA wraps. Histone acetylation is
brought about by HATs and is usually associated with gene activation where
histone deacetylation is brought on by HDACs and is associated with gene
repression.

These changes, unlike DNA sequence mutation, are potentially

reversible if the specific enzymes facilitating the modifications are targeted.
Therefore, epigenetic therapy has the potential to target cancer through silencing
of oncogenes or activation of silenced TSG’s [256].
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The Brattain laboratory has extensively documented the anti-tumorigenic
abilities of the TSG TGF RII. Previous work confirmed that the HDACi
Belinostat induces expression of TGF RII [211]. However two aspects of the
silencing of TGF RII were not understood: – (i) the role of specific HDACs
involved in the silencing, and (ii) the potential role of HMTs in the silencing of
TGF RII.
We hypothesized that identification of the specific HDACs and/or HMTs
involved in the silencing of TGF RII will allow us to develop drugs specific to
those HDACs and/or HMTs, so reducing off-target effects resulting in reduced
toxicities. We employed both pharmacological and genetic approaches to
indentify the specific epigenetic regulators involved in the epigenetic silencing of
TGF RII.
We treated CRC cell lines with MGCD0103, which selectively inhibits HDACs 1,
2, 3 and 11 at nanomolar values [235]. Inhibition of these HDACs resulted in an
induction of TGF RII in FET cells at 48 hrs and in CBS cells at 24 hrs as well as 48
hrs. FET is a non-metastatic cell line that expresses low-level autocrine TGF
signaling. In contrast CBS is a metastatic cell line with silenced TGF RII
expression and so lacks inhibitory TGF signaling. MGCD0103 caused a robust
re-expression of TGF RII confirming that HDAC1, 2, 3 and/or 11 are probably
involved in its silencing. In contrast, treatment with Droxinostat, which inhibits
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HDAC 6 and 8 (IC50 2.47µm and 1.46µm, respectively) and HDAC3 at high
micromolar concentration (IC50 = 20µm) did not induce TGF RII [239, 240].
There appeared to be slight induction of the TGF RII expression at the 25µm
dose at which HDAC3 would be inhibited. These pharmacological studies
pointed to the involvement of of HDACs 1 and 3 in the epigenetic silencing of
TGF RII.
In order to confirm the roles of HDACs 1 and 3 , we developed stable HDAC1
knockdown clones in both FET and CBS cell lines. We successfully developed the
HDAC2 KD as a control. The KD of HDAC1 resulted in re-expression of
TGF RII. The same result was observed upon KD of HDAC3 but HDAC2 had no
effect on TGF RII expression. This confirmed that HDACs 1 and 3 are the major
HDACs involved in the epigenetic silencing of TGF RII. Based on the work
done, we were able to confirm the roles of HDACs 1 and 3 in the silencing of the
TSG TGF RII.
Histone methylation is also involved in epigenetic silencing. G9a is a H3K9
methyltransferase while EZH2 is a H3K9 as well as H3K27 methyltransferase.
These methytransferases are capable of di- and tri-methylation and can be
associated with gene activation or repression. There is no literature published
confirming a relationship between G9a and the epigenetic silencing of TGF RII.
While the relationship between the cytokine TGF and EZH2 has been studied,
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the potential role of EZH2 in the epigenetic silencing of TGF RII has not been
investigated. We therefore examined the role of G9a and EZH2 in the silencing of
TGF RII.
UNC0638 inhibits both G9a and its partner GLP at low nanomolecular levels
[242]. On treating the CRC cell lines with this drug we observed an induction of
TGF RII in a time and dose-dependent manner. Reactivation of the TGF
inhibitory pathway was confirmed by the phosphorylation of Smad3. We were
able to obtain similar results by the inhibition of EZH2 by DZNEP [245]. These
preliminary studies confirmed that G9a as well as EZH2 play a role in the
silencing of TGF RII and contribute to tumorigenesis as well progression of
CRC.
These findings also raised an inherent question. HDACi’s such as Belinostat and
MGCD0103 are sufficient to induce re-expression of TGF RII but clearly histone
methylation is involved in the silencing too. We therefore hypothesize that
HDACi’s might regulate the HMTs, G9a and EZH2. Panobinostat, a pan-HDACi
decreased EZH2 levels in acute leukemia cells and enhanced cancer cell survival
[257]. Belinostat treatment of the FET CRC cells decreased G9a and EZH2.
Therefore, though HDACi’s predominantly regulate histone deacetylation at
gene promoters, they can also play a role in histone methylation status through
down regulation of HMTs.
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Future Directions:
Chromatin Immunoprecipitation studies of the TGF RII promoter will
give insight of the on the actual interaction between the HDACs 1 and 3
and the promoter region.
Confirm that the knockdown of HDACs 1 and 3 allows for active
inhibitory TGF

signaling by examining the phosphorylation status of

Smad3. Confirm that re-expression of TGF RII decreases survivin and
XIAP through western blot analysis.
Knockdown of G9a and EZH2 using siRNA and confirmation of their
association

with

the

TGF RII

promoter

using

chromatin

immunoprecipitation.
Confirm that knockdown of G9a and EZH2 activates the inhibitory TGF
signaling pathway by examining the phosphorylation status of Smad3.
Confirm that re-expression of TGF RII decreases survivin and XIAP
through western blot analysis .

Conclusions:
My study has confirmed the role of HDACs 1 and 3 in the silencing of TSG
TGF RII in CRC. We also confirmed that HDACi’s have the ability not only to
inhibit HDACs but also to regulate HMTs to effect silencing of TSG’s.
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